Don’t let the headline confuse you. The American Bar Association doesn’t usually do clinical guidance. But earlier this year, the ABA’s Health Law eSource published a detailed framework for how ibogaine clinical trial sponsors should structure their safety monitoring, complete with cardiac escalation thresholds, independent oversight requirements, and documentation standards that would hold up in court.
Read it carefully and you’ll realize they accidentally wrote something else: a checklist patients should be asking their clinic about before they ever swallow a dose.
The piece, “Building Litigation-Ready Safety Architecture for High-Risk Therapeutics: Lessons from Ibogaine’s Cardiac Risk” (ABA members only; archived copy linked) was written by attorneys Kimberly Chew and Odette Hauke. Their audience is the drug developers, research institutions, and lawyers running and advising clinical trials. Their goal is litigation resilience, not patient safety per se. But the two overlap enough that the distinction gets blurry fast.
Here’s the core problem they’re solving. Ibogaine inhibits the hERG potassium channel at clinically relevant concentrations. That creates mechanistic risk for QT interval prolongation, and in the worst cases, ventricular arrhythmias and cardiac arrest. (The QT interval is the time it takes the heart’s lower chambers to electrically activate and recover. Prolonging it increases the risk of dangerous rhythm disturbances.) Studies show ibogaine causes a maximum QTc prolongation of roughly 68 milliseconds. Clinical protocols flag anything over 500 milliseconds as a threshold requiring immediate action.
Courts have already held that where a risk is scientifically foreseeable, sponsors must implement safeguards commensurate with that risk. The ABA’s conclusion is unambiguous: if you’re running an ibogaine trial and you don’t have an independent safety monitoring board, a cardiologist on that board, pre-specified QTc escalation triggers, and rigorous contemporaneous documentation of every adverse event, “the failure to implement robust safety architecture would be difficult to defend.”
That sentence is written for lawyers, but translate it into plain English and it says something important: knowing what we know about ibogaine’s cardiac risk, operating without these safeguards is, at minimum, legally indefensible.
